T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Blood Adv. 2019 Oct 8;3(19):2812-2815. doi: 10.1182/bloodadvances.2019000600.

Alfred L Garfall¹, Ehren K Dancy², Adam D Cohen¹, Wei-Ting Hwang³, Joseph A Fraietta^{4

5

6}, Megan M Davis^{5

6}, Bruce L Levine^{5

6}, Don L Siegel^{5

6}, Edward A Stadtmauer¹, Dan T Vogl¹, Adam Waxman¹, Aaron P Rapoport⁷, Michael C Milone^{5

6}, Carl H June^{5

6}, J Joseph Melenhorst^{5

6}

¹ Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center.
² Department of Medicine.
³ Department of Biostatistics, Epidemiology and Informatics, Abramson Cancer Center.
⁴ Department of Microbiology.
⁵ Department of Pathology and Laboratory Medicine, and.
⁶ Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and.
⁷ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.

Abstract

T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients.
CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.